La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !
Zevra Therapeutics Gestione
Gestione criteri di controllo 0/4
Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.
Informazioni chiave
Neil McFarlane
Amministratore delegato
US$3.4m
Compenso totale
| Percentuale dello stipendio del CEO | 4.6% |
| Mandato del CEO | less than a year |
| Proprietà del CEO | n/a |
| Durata media del management | 1.6yrs |
| Durata media del Consiglio di amministrazione | 1.3yrs |
Aggiornamenti recenti sulla gestione
Recent updates
Zevra Therapeutics, Inc.'s (NASDAQ:ZVRA) 26% Jump Shows Its Popularity With Investors
Jul 12
Analysts Just Shaved Their Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Forecasts Dramatically
Apr 07Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Just Reported And Analysts Have Been Cutting Their Estimates
Apr 04Zevra Therapeutics, Inc.'s (NASDAQ:ZVRA) Stock Retreats 27% But Revenues Haven't Escaped The Attention Of Investors
Apr 02Investors Appear Satisfied With Zevra Therapeutics, Inc.'s (NASDAQ:ZVRA) Prospects
Dec 28Bullish: Analysts Just Made A Noticeable Upgrade To Their Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Forecasts
Sep 05This Just In: Analysts Are Boosting Their Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Outlook for This Year
Aug 20Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Stocks Shoot Up 31% But Its P/S Still Looks Reasonable
Apr 17US$18.00: That's What Analysts Think Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Is Worth After Its Latest Results
Mar 10Is Zevra Therapeutics (NASDAQ:ZVRA) Using Debt In A Risky Way?
Mar 08Bearish: Analysts Just Cut Their KemPharm, Inc. (NASDAQ:KMPH) Revenue and EPS estimates
Nov 16Does KemPharm (NASDAQ:KMPH) Have A Healthy Balance Sheet?
Nov 11KemPharm posts Phase 1 data to support further studies for sleep disorder therapy
Sep 28KemPharm wins Buy rating at Canaccord on CNS focus
Sep 15KemPharm - Redesigning Approved Drugs For Better Efficacy And Safety
Jun 28KemPharm exercises existing warrants and issues new ones in private placement
Jun 18KemPharm reports orange book listing for six U.S. patents covering serdexmethylphenidate
May 26Analisi delle retribuzioni degli amministratori delegati
| Data | Compenso totale | Stipendio | Guadagni aziendali |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$67m |
| Mar 31 2024 | n/a | n/a | -US$49m |
| Dec 31 2023 | US$3m | US$158k | -US$46m |
Compensazione vs Mercato: La retribuzione totale di Neil ($USD 3.45M ) è superiore alla media delle aziende di dimensioni simili nel mercato US ($USD 2.44M ).
Compensazione vs guadagni: Dati insufficienti per confrontare la retribuzione di Neil con le performance aziendali.
AMMINISTRATORE DELEGATO
Neil McFarlane (51 yo)
less than a year
Mandato
US$3,445,231
Compensazione
Mr. Neil F. McFarlane serves as President & Chief Executive Officer at Zevra Therapeutics, Inc. since October 10, 2023 and serves as its Director since October 9, 2023. He has served as Director at Collegi...
Gruppo dirigente
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| President | less than a year | US$3.45m | Nessun dato | |
| Co-Founder & Chief Development Officer | no data | US$1.67m | 0.052% $ 197.6k | |
| CFO, Secretary & Treasurer | 9.2yrs | US$2.26m | 0.035% $ 134.1k | |
| Chief Commercial Officer & Executive VP of Business Development | 1.6yrs | US$1.82m | 0.0066% $ 25.4k | |
| Chief Scientific Officer | 1.6yrs | US$1.08m | 0.0052% $ 19.9k | |
| Vice President of Investor Relations & Corporate Communications | 2yrs | Nessun dato | Nessun dato | |
| Chief Legal Officer | less than a year | Nessun dato | Nessun dato | |
| Chief People Officer | less than a year | Nessun dato | Nessun dato | |
| Senior Vice President of Manufacturing | 1.6yrs | Nessun dato | Nessun dato | |
| Senior Vice President of Clinical Development | 1.6yrs | Nessun dato | Nessun dato | |
| Senior Vice President of Medical Affairs & Advocacy | 1.6yrs | Nessun dato | Nessun dato | |
| Chief Medical Officer | less than a year | Nessun dato | Nessun dato |
1.6yrs
Durata media
52yo
Età media
Gestione esperta: Il team dirigenziale di ZVRA non è considerato esperto (durata media 1.6 anni), il che suggerisce un nuovo team.
Membri del Consiglio di amministrazione
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| President | less than a year | US$3.45m | Nessun dato | |
| Independent Director | 1.3yrs | US$274.00k | 0% $ 0 | |
| Independent Director | 1.3yrs | US$258.02k | 0% $ 0 | |
| Independent Chair | 3yrs | US$324.39k | 0.0014% $ 5.2k | |
| Member of Scientific and Medical Advisory Board | no data | Nessun dato | Nessun dato | |
| Independent Director | 1.3yrs | US$264.31k | 0.057% $ 217.8k | |
| Independent Director | 1.3yrs | US$260.67k | 0.0019% $ 7.3k | |
| Chairman of Scientific and Medical Advisory Board | 17.6yrs | Nessun dato | Nessun dato | |
| Member of Scientific & Medical Advisory Board | no data | Nessun dato | Nessun dato | |
| Co-Chair of Physician Advisory Council | 10.8yrs | Nessun dato | Nessun dato | |
| Co-Chair of Physician Advisory Council | 10.8yrs | Nessun dato | Nessun dato | |
| Independent Director | less than a year | US$243.04k | 0.038% $ 145.2k |
1.3yrs
Durata media
58yo
Età media
Consiglio di amministrazione esperto: Il consiglio di amministrazione di ZVRA non è considerato esperto (durata media del mandato 1.3 anni), il che suggerisce un nuovo consiglio.